Figure 3From: A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899Changes in quality of life from baseline to week 9/10 (day 2 of cycle 4 for Arm A and day 1 of cycle 2 for Arm B).Back to article page